Itepekimab SAR440340

DRUG3 trials

Sponsors

Sanofi

Conditions

Chronic Obstructive Pulmonary Disease

Phase 2

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

CompletedNCT05326412

SanofiChronic Obstructive Pulmonary Disease

Start: 2022-05-19End: 2025-07-25Updated: 2026-08-31

Phase 3

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT04701983

SanofiChronic Obstructive Pulmonary Disease

Start: 2020-12-16End: 2025-08-27Updated: 2026-04-15

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT04751487

SanofiChronic Obstructive Pulmonary Disease

Start: 2021-02-12End: 2025-08-28Updated: 2026-04-15

Related Papers

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Clinical and Translational Science2024-07-309 citations

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

ERJ Open Research2024-05-0921 citations